Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01IUS
|
|||
Former ID |
DIB002240
|
|||
Drug Name |
Mapracorat
|
|||
Synonyms |
BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Ocular disease [ICD-11: 1F00.1Z] | Phase 3 | [1], [2] | |
Company |
Bayer Schering Pharma AG
|
|||
Structure |
Download2D MOL |
|||
Formula |
C25H26F4N2O2
|
|||
Canonical SMILES |
CC1=NC2=C(C=C1)C(=CC=C2)NCC(CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O
|
|||
InChI |
1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1
|
|||
InChIKey |
VJGFOYBQOIPQFY-XMMPIXPASA-N
|
|||
CAS Number |
CAS 887375-26-0
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucocorticoid receptor (NR3C1) | Target Info | Agonist | [3] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
NetPath Pathway | IL2 Signaling Pathway | |||
TCR Signaling Pathway | ||||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
Signaling events mediated by HDAC Class II | ||||
FOXA2 and FOXA3 transcription factor networks | ||||
Glucocorticoid receptor regulatory network | ||||
Regulation of Androgen receptor activity | ||||
AP-1 transcription factor network | ||||
Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
SIDS Susceptibility Pathways | ||||
Nuclear Receptors Meta-Pathway | ||||
Endoderm Differentiation | ||||
Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
Adipogenesis | ||||
Circadian Clock | ||||
Nuclear Receptors |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8643). | |||
REF 2 | ClinicalTrials.gov (NCT01298752) Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery. U.S. National Institutes of Health. | |||
REF 3 | Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009 Oct;158(4):1088-103. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.